CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CANDESARTA	IM	*USP39–NF34*	2895	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Row 3 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	PURITIES/*Organic Impurities*							Column 1 of *Table 6*:Change Candesartan related compound A[b,c] to: Candesartan cilexetil related compound A[b,c]
MEMANTINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official October 01, 2015)*	Online	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Analysis*: Change of USP Memantine Related Compound E RS or to: of memantine related compound E or AND In the variable definition list: Change r_U = peak response of USP Memantine Related Compound E

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS or any individual degradation product from the *Sample solution* to: r_U = peak response of memantine related compound E or any individual degradation product from the *Sample solution*
RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS	4. HCP IMMUNOASSAY METHOD VALIDATION/*4.3 Sample Linearity*/*Table 4*	*Second Supplement to USP38–NF33*	7647	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	*Product* column: Change 10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16 to: 10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625 AND *Sample 1/HCP ratio* column: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6 to: 4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6 AND *Sample 2/HCP ratio* column: Change 2.0, 3.3, 4.0, 5.9, 5.3, 6.1, <6 to: 2.00, 3.30, 4.00, 5.92, 5.28, 6.08, <6 AND *Sample 3/HCP ratio* column: Change 0.3, 0.5, 0.6, 0.9, 1.4, <6, <6 to: 0.32, 0.50, 0.60, 0.88, 1.44, <6, <6 AND *Sample 3/% max ratio value* column: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								83% to: 61%
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS/ *Physicochemical Tests/ Absorbance*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Plasticized polyvinyl chloride*: Delete Additionally, for nonplasticized polyvinyl chloride materials only, determine the spectrum between 250 and 330 nm in the alcohol sample associated with *Solution S6*.
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER	IMPURITIES/*Limit of Methacrylic Acid and Ethyl Acrylate*	*First Supplement to USP39–NF34*	Online	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 5 of *Standard solution*: Change Mix 10.0 mL of this solution to: Mix 5.0 mL of this solution AND Line 7 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution: Change about 0.67 µg/mL to: about 0.5 µg/mL Line 4 of *Sample solution*: Change 10.0 mL of this solution to: 5.0 mL of this solution AND In the variable definition list in *Analysis*: Change V_F = final volume of the *Sample solution*, 15 mL *D* = dilution factor for preparation of the *Sample solution*, 5 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ARGININE HYDROCHLORIDE	SPECIFIC TESTS/*Chloride Content*	*USP38–NF33*	2279	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	V_F = final volume of the *Sample solution*, 10 mL *D* = dilution factor for preparation of the *Sample solution*, 10 Delete the subsection *Blank*: 140 mL of water and 1 mL of dichlorofluorescein TS AND The equation in the *Analysis*: Change Result = [(*V* ? *B*) × *N* × *F* × 100]/*W* to: Result = (*V* × *N* × *F* × 100)/*W* AND Line 10 of *Analysis*: Delete *B* = *Blank* titrant volume (mL)
PLASTIC	TEST	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Column 4 of *S3*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MATERIALS OF CONSTRUCTION	METHODS/*Extractions*/*Table 3*							row: Change Extractable metals: Al, Sb, As, Ba, Cd, Co, Ge, Hg, Mn, Ni, Pb, Ti, V, and Zn to: Extractable metals: Al, As, Ba, Cd, Co, Hg, Mn, Ni, Pb, Ti, V, and Zn
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION	ASSAY/*Procedure*	*USP39–NF34*	3529	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *System suitability solution*:Change USP Diphenhydramine Hydrochloride Related Compound A RS to: USP Diphenhydramine Related Compound A RS AND Line 4 of *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability: Change for diphenhydramine hydrochloride related compound A and diphenhydramine hydrochloride are to: for diphenhydramine related compound A and diphenhydramine are
PLASTIC MATERIALS OF CONSTRUCTION	SPECIFICATIONS/ *Polyethylene/Extractable Metals*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Zirconium*: Change 1 µg/g. to: 0.1 µg/g.
DISSOLUTION	INTERPRETATION/*Immediate-Release Dosage Forms*/ *Immediate-Release Dosage Forms*	*USP39–NF34*	540	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Row 3 of Column 1 of *Acceptance Table for a Pooled Sample*: Change S_1 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Pooled Sample							S_2 AND Row 4 of Column 1 of *Acceptance Table for a Pooled Sample*: Change S_1 to: S_3
DIGOXIN	IM PURITIES/*Related Glycosides*/*System suitability*	*Interim Revision Announcement (Official November 01, 2015)*	Online	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 2: Change *Sample: System suitability solution* to: *Samples: System suitability solution* and *Standard solution* AND Line 2 of *Suitability requirements*: Change *Resolution:* NLT 1.5 between the digoxin and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lanatoside C peaks *Relative standard deviation:* NMT 2.0%, determined from the digoxin peak in replicated injections to: *Resolution:* NLT 1.5 between the digoxin and lanatoside C peaks, *System suitability solution* *Relative standard deviation:* NMT 2.0%, determined from the digoxin peak in replicated injections, *Standard solution*
HYDROCHLOR	ASSAY/	*USP38–NF33*	3770	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second*	Line 8 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IC ACID INJECTION	*Procedure*						*Supplement to USP39–NF34*	*Analysis*: Change *F* = equivalency factor, 18.23 mg/mEq to: *F* = equivalency factor, 36.46 mg/mEq
DONEPEZIL HYDROCHLORIDE	IMPURITIES/*Organic Impurities/Procedure 2*	*First Supplement to USP38–NF33*	7384	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Footnote h of *Table 3*: Change 1-Benzyl-4-[(5,6-dimethoxyinda n-2-yl)methyl]piperidine. to: 1-Benzyl-4-[(5,6-dimethoxyinden-2-yl)methyl]piperidine.
DEXAMETHASONE SODIUM PHOSPHATE INJECTION	ASSAY/*Procedure*	*Interim Revision Announcement (Official May 01, 2015)*	Online	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 9 of *Analysis*: Change C_S = concentration of USP Dexamethasone Sodium Phosphate RS in the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (µg/mL) to: C_S = concentration of USP Dexamethasone Sodium Phosphate RS in the *Standard solution* (mg/mL)
GALANTAMINE HYDROBROMIDE	IMPURITIES/*Organic Impurities*	*USP38–NF33*	3646	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 8 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times (100/100 ? L)$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times (100/[100 ? L])$
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE	CHEMICAL INFORMATION	*USP38–NF33*	6074	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 5: Change [38899-05-7]. to: [1296149-08-0] .
ALTEPLASE FOR INJECTION	ASSAY/ *Biological Potency*	*USP39–NF34*	2401	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Human thrombin solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RISPERIDONE TABLETS	*Assay*	*USP38–NF33*	5195	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Change 33 Units in terms of the U.S. Standard Thrombin/mL in *Buffer* to: 33 U.S. Units in terms of the U.S. Standard Thrombin/mL in *Buffer* AND Line 5 of *Analysis*: Change *Standard solution* and *Sample solution*, to: *Standard solution* or *Sample solution*, Line 4 of *Procedure*: Change Calculate the quantity, in mg, of risperidone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Calculate the percentage of the labeled amount of risperidone
IMIQUIMOD CREAM	SPECIFIC TESTS/*pH <791>*	*First Supplement to USP38–NF33*	7409	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Sample*: Change Nominally 50 mg/mL of imiquimod from Cream in water. to: Nominally 2.5 mg/mL of imiquimod from Cream in water.
DEXAMETHASONE SODIUM PHOSPHATE OPHTHALMIC SOLUTION	ASSAY/ *Procedure*	*Interim Revision Announcement (Official May 01, 2015)*	Online	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 9 of *Analysis*: Change C_S = concentration of USP Dexamethasone Sodium Phosphate RS in the *Standard solution* (µg/mL) to: C_S = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Dexamethasone Sodium Phosphate RS in the *Standard solution* (mg/mL)
GALANTAMINE TABLETS	PERFORMANCE TESTS/ *Dissolution*	*USP38–NF33*	3649	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 6 of *Analysis* in *Test 1*: Change Result = $(A_U/A_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(A_U/A_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times V \times 100$ AND Add to the variable definition list in *Test 1* V = volume of *Medium*, 500 mL AND Equation in *Test 3*: Change Result = $(r_U/r_S) \times (C_S/L) \times (M$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times V \times 100$ AND Add to the variable definition list in *Test 3* *V* = volume of *Medium*, 500 mL
GLUCOSAMINE SULFATE SODIUM CHLORIDE	CHEMICAL INFORMATION	*USP38–NF33*	6075	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 5: Change [38899-05-7]. to: [1296149-13-7].
ROPINIROLE TABLETS	IMPURITIES/*Organic Impurities*	*USP39–NF34*	5756	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Footnote b of *Table 2*: Change 4-[2-(Dipropylnitroryl)ethyl]-1,3-dihydrox-2*H*-indol-2-one. to: *N*-[2-(2-Oxoindolin-4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-yl)eth yl]-*N* -propylpropan-1 -amine oxide.
DEXTROAMPHETAMINE SULFATE	ASSAY/ *Procedure*	*USP38–NF33*	3060	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *System suitability solution*: Change 0.02 µg/mL each of USP Dextroamphetamine Related Compound A RS and USP Dextroamphetamine Related Compound B RS in *Standard solution* to: Transfer about 40 mL of the *Standard solution* to a 50-mL volumetric flask. Using a microliter syringe, add 1 µL each of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dextroamphetamine Related Compound A RS and USP Dextroamphetamine Related Compound B RS. Dilute with *Standard solution* to volume.
TAMSULOSIN HYDROCHLORIDE CAPSULES	ASSAY/ *Procedure 8*	*USP38–NF33*	5442	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Standard solution*: Change Prepare a solution containing 1.0 mg/mL of USP Tamsulosin Hydrochloride RS in methanol. to: Prepare a solution containing 0.1 mg/mL of USP Tamsulosin Hydrochloride RS in methanol. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 6 of *Sample solution*: Change Add 30 mL of *Mobile phase*, and shake by mechanical means for 30 min. to: Add 30 mL of *Mobile phase*, shake by mechanical means for 30 min, and dilute with *Mobile phase* to volume.
ALTEPLASE	ASSAY/ *Biological Potency*	*USP39–NF34*	2398	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Human thrombin solution*: Change 33 Units in terms of the U.S. Standard Thrombin/mL in *Buffer* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								33 U.S. Units in terms of the U.S. Standard Thrombin/mL in *Buffer* AND Line 5 of *Analysis*: Change *Standard solution* and *Sample solution*, to: *Standard solution* or *Sample solution*,
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 9*	*Revision Bulletin (Official December 01, 2015)*	Online	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 4 of *Medium*: Change 6 g/L to: 10 g/L
ATOMIC ABSORPTION SPECTROSCOPY	VALIDATION AND VERIFICATION/ *Precision/Intermediate Precision*	*USP38–NF33*	649	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3: Change As a minimum, the analytical procedure should be assessed by performing the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								repeatability test in any of the conditions previously mentioned (totaling 12 measurements). to: As a minimum, the analytical procedure should be assessed by performing the repeatability test in any combination of at least two of the conditions previously mentioned (totaling 12 measurements).
OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION	IMPURITIES/*Limit of Late Eluting Impurities*	*USP38–NF33*	4625	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Add [Note–Protect solutions from light.]
MILK THISTLE	COMPOSITION /*Content of Silymarin*	*Second Supplement to USP38–NF33*	7878	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3 of *Sample stock solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Transfer the thimble to a continuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and discard the hexane. Dry the extraction thimble to remove residual hexane, to: Transfer the thimble to a continuous-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of solvent hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and discard the solvent hexane. Dry the extraction thimble to remove residual solvent hexane,
LOPINAVIR AND RITONAVIR ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*Second Supplement to USP38–NF33*	8139	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Row 17 of Column 3 of *Table 2*: Change 0.2 to: 0.2[p]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Add footnote [p]Disregard any peak less than 0.01%.
ISOSORBIDE MONONITRATE TABLETS	*USP Reference standards <11>*	*USP38–NF33*	3974	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 2 of USP Diluted Isosorbide Mononitrate Related Compound A RS: Change 1,4:3,5-Dianhydro-D-glucitol 2-nitrate. to: 1,4:3,6-Dianhydro-D-glucitol 2-nitrate.
METAXALONE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP38–NF33*	7432	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 2 of *Buffer, Mobile phase, Chromatographic system,* and *System suitability*: Change Proceed as directed in the *Assay*. to: Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed in the *Assay*, except use 270 nm for analysis. AND Line 10 of *Analysis*: Change *V* = volume of the *Medium*, 750 mL to: *V* = volume of the *Medium*, 900 mL
CORTICOTROPIN FOR INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP38–NF33*	8061	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 7 of *Replication*: Change (see <111>, *Confidence Intervals for Individual Assays*). to: (see <111>, *The Confidence Interval and Limits of Potency*).
PACKAGING AND	GENERAL DEFINITIONS	*USP38–NF33*	447	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to*	Line 1 of *Single-Dose* (see also

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
STORAGE REQUIREMENTS							*USP39–NF34*	*Injections <1>, Containers for Injections*): Change A single-unit package for an article intended for parenteral administration. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled. to: A single-unit package for an article intended for parenteral administration. A single-dose container is labeled as such. Examples of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled.
CYCLOBENZAPRINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities/Analysis*	*USP38–NF33*	2972	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3: Change Calculate the percentage of any individual unspecified degradation product to: Calculate the percentage of any individual degradation product AND Line 6: Change r_U = peak response of any individual unspecified degradation

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								product from the *Sample solution* to: r_U = peak response of any individual degradation product from the *Sample solution*
LIGHT MINERAL OIL	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*USP38–NF33*	6763	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Acceptance criteria*: Change The *Sample* may turn hazy, but it remains colorless, or shows a slight pink or yellow color, and the *Sample* does not become darker than the *Standard solution*. to: The oil portion of the *Sample* may turn hazy, but it remains

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								colorless or shows a slight pink or yellow color, and the acid portion of the *Sample* does not become darker than the *Standard solution*.
POWDERED MILK THISTLE	COMPOSITION /*Content of Silymarin*	*Second Supplement to USP38–NF33*	7880	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3 of *Sample stock solution*: Change Transfer the thimble to a con tinuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								round-bottom flask from the extraction apparatus, and discard the hexane. Dry the extraction thimble to remove residual hexane, to: Transfer the thimble to a con tinuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of solvent hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								discard the solvent hexane. Dry the extraction thimble to remove residual solvent hexane,
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP38–NF33*	8158	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Row 6 of Column 2 of *Table 5*: Change 0.62 to: 0.82
INHALATION AND NASAL DRUG PRODUCTS—AEROSOLS, SPRAYS, AND POWDERS—PERFORMANCE QUALITY TESTS	C. AERODYNAMIC SIZE DISTRIBUTION—INHALATION AEROSOLS, SPRAYS, AND POWDERS	*USP38–NF33*	388	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 13 of paragraph 2 of *C.3 Apparatus 2 for Inhalation Powders—Marple Miller Impactor*/*C.3.1 Design—Apparatus 2*: Change Adjust the timer controlling the operation of the two-way solenoid valve so that it opens this valve for a duration of *T*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								seconds as determined during testing for *Delivered-Dose Uniformity*. to: Adjust the timer controlling the operation of the two-way solenoid valve so that it opens this valve for a duration such that the total volume sampled is at least 4 L. AND Line 3 of paragraph 2 of *C.4 Apparatus 3 for Inhalation P owders—Anders en Impactor (with pre-separator)*/*C.4.1 Design—Apparat us 3*: Change Once the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								product is positioned, discharge the powder into the apparatus by activating the timer and opening the two-way solenoid valve for the required duration, *T* ± 5%, as determined during testing for *Delivered-Dose Uniformity*. to: Once the product is positioned, discharge the powder into the apparatus by activating the timer and opening the two-way solenoid valve for the required

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								duration such that the total volume sampled is at least 4 L. AND Line 19 of paragraph 2 of *C.5 Apparatus 4 for Inhalation Powders—Multistage Liquid Impinger*/*C.5.1 Design—Apparatus 4*: Change Adjust the timer controlling the operation of the two-way solenoid valve so that it opens the valve for the same duration, *T*, as used during testing for *Delivered-Dose Uniformity*. to: Adjust the timer controlling the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								operation of the two-way solenoid valve so that it opens the valve for the duration such that the total volume sampled is at least 4 L. AND Line 9 of paragraph 4 of *C.6 Apparatus 5 for Inhalation Powders—Next Generation Impactor (with pr e- separator)*/*C.6.2 Procedure—App aratus 5*: Change Adjust the timer controlling the operation of the two-way solenoid valve so that it opens the valve for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								same duration, *T*, as used during testing for *Delivered-Dose Uniformity*. to: Adjust the timer controlling the operation of the two-way solenoid valve so that it opens this valve for a duration such that the total volume sampled is at least 4 L.
OLMESARTAN MEDOXOMIL	IMPURITIES/*Organic Impurities*	*USP38–NF33*	4622	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Footnote d of *Impurity Table*: Change (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2?-(2-trityl-1*H*-tetrazol-5-yl)biphenyl-4-yl)meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl)-1*H*-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2?-(2-trityl-2*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate.
DESCRIPTION AND SOLUBILITY	SUNFLOWER OIL	*Second Supplement to USP38–NF33*	7761	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 5: Change *NF category*: Coating agent; emollient; solvent; tablet and/or capsule diluent; vehicle (oleaginous). to: *NF category*: Coating agent; emollient; solvent; diluent; vehicle (oleaginous).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
REPOSITORY CORTICOTROPIN INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP38–NF33*	8063	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 7 of *Replication*: Change (see <111>, *Confidence Intervals for Individual Assays*). to: (see <111>, *The Confidence Interval and Limits of Potency*).
DILUTED ISOSORBIDE MONONITRATE	*USP Reference standards <11>*	*USP38–NF33*	3973	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 2 of USP Diluted Isosorbide Mononitrate Related Compound A RS: Change 1,4:3,5-Dianhydro-D-glucitol 2-nitrate. to: 1,4:3,6-Dianhydro-D-glucitol 2-nitrate.
CEFDINIR FOR ORAL SUSPENSION	PERFORMANCE TESTS/	*First Supplement to USP38–NF33*	7357	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 5 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Dissolution <711>							Result = $(A_U/A_S) \times C_S \times d \times V \times D \times (1/L) \times 100$ to: Result = $(A_U/A_S) \times C_S \times (d/W_U) \times V \times D \times (1/L) \times 100$ AND Add to the variable definition list W_U = weight of reconstituted Cefdinir for Oral Suspension taken (mg)
CORTICOTROPIN INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP38–NF33*	8059	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 7 of *Replication*: Change (see <111>, *Confidence Intervals for Individual Assays*). to: (see <111>, *The Confidence Interval and Limits of Potency*).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MANNITOL INJECTION	*Specific rotation <781>*	*Second Supplement to USP38–NF33*	Online	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1: Change Transfer an accurately measured volume of Injection, equivalent to about 1 g of mannitol as determined by the *Assay*, to a 100-mL volumetric flask:it meets the requirements of the test for *Specific rotation* under *Mannitol*. to: +137° to +145°.Transfer an accurately measured volume of Injection, equivalent to about 1 g of mannitol as determined by the *Assay*, to a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								100-mL volumetric flask. Add 40 mL of a 1-in-10 ammonium molybdate solution, previously filtered if necessary. Add 20 mL of 1 N sulfuric acid, and dilute with water to volume.
RIVASTIGMINE	IMPURITIES/*Organic Impurities*	*USP38–NF33*	5212	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Row 3 of Column 1 of *Table 1*: Change Nor impurity (rivastigmine related compound B) to: Nor impurity[a] AND Add footnote a: [a](*S*)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcar

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bamate (racemic mixture is rivastigmine related compound B).
ROPIVACAINE HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP38–NF33*	5227	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Ropivacaine Related Compound B RS: Change (*R*)-ropivacaine hydrochloride monohydrate; (*R*)-(?)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-di

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methylphenyl)-amide hydrochloride monohydrate.
CALCIUM LACTATE TABLETS	ASSAY/ *Procedure*	*USP38–NF33*	2553	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 3 of *Analysis*: Change While stirring, add 30 mL of *Titrant* from a 50-mL buret. to: While stirring, add 15 mL of *Titrant* from a 50-mL buret.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31

- …
- Next page Next ›
- Last page Last »